Bayer seals $2.9B acquisition of Norway's Algeta


Bayer (BAYZF) is on course to acquire partner Algeta (ALGZF) after the German company received acceptance representing 92.17% of the Norwegian company's stock for its $2.9B bid.

Bayer has also extended the acceptance deadline of the offer by two days to Wednesday and it expects to close the deal in Q1.

The acquisition will give Bayer full control of Xofigo, a prostate-cancer treatment that the German drugs and chemicals firm has developed with Algeta since 2009.

Bayer views Xofigo, which was launched in the U.S. last year, as one of its five most important new medicines. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs